Life Insurance Corporation of India

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, LICI.BO has a market cap of 4.7T. Regarding current trading prices, LICI.NS is priced at ₹746.00, while LICI.BO trades at ₹745.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas LICI.BO's P/E ratio is 9.22. In terms of profitability, LICI.NS's ROE is +0.18%, compared to LICI.BO's ROE of +0.18%. Regarding short-term risk, LICI.NS is more volatile compared to LICI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LICI.NS.Check LICI.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, SBILIFE.NS has a market cap of 1.8T. Regarding current trading prices, LICI.NS is priced at ₹746.00, while SBILIFE.NS trades at ₹1,790.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas SBILIFE.NS's P/E ratio is 72.49. In terms of profitability, LICI.NS's ROE is +0.18%, compared to SBILIFE.NS's ROE of +0.14%. Regarding short-term risk, LICI.NS is less volatile compared to SBILIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check SBILIFE.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, SBILIFE.BO has a market cap of 1.8T. Regarding current trading prices, LICI.NS is priced at ₹746.00, while SBILIFE.BO trades at ₹1,789.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas SBILIFE.BO's P/E ratio is 72.41. In terms of profitability, LICI.NS's ROE is +0.18%, compared to SBILIFE.BO's ROE of +0.14%. Regarding short-term risk, LICI.NS is less volatile compared to SBILIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check SBILIFE.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, HDFCLIFE.BO has a market cap of 1.2T. Regarding current trading prices, LICI.NS is priced at ₹746.00, while HDFCLIFE.BO trades at ₹573.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas HDFCLIFE.BO's P/E ratio is 65.31. In terms of profitability, LICI.NS's ROE is +0.18%, compared to HDFCLIFE.BO's ROE of +0.11%. Regarding short-term risk, LICI.NS is less volatile compared to HDFCLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check HDFCLIFE.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, HDFCLIFE.NS has a market cap of 1.2T. Regarding current trading prices, LICI.NS is priced at ₹746.00, while HDFCLIFE.NS trades at ₹572.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas HDFCLIFE.NS's P/E ratio is 65.18. In terms of profitability, LICI.NS's ROE is +0.18%, compared to HDFCLIFE.NS's ROE of +0.11%. Regarding short-term risk, LICI.NS is less volatile compared to HDFCLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check HDFCLIFE.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, ICICIPRULI.BO has a market cap of 743.7B. Regarding current trading prices, LICI.NS is priced at ₹746.00, while ICICIPRULI.BO trades at ₹513.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas ICICIPRULI.BO's P/E ratio is 54.27. In terms of profitability, LICI.NS's ROE is +0.18%, compared to ICICIPRULI.BO's ROE of +0.11%. Regarding short-term risk, LICI.NS is less volatile compared to ICICIPRULI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check ICICIPRULI.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, ICICIPRULI.NS has a market cap of 743.7B. Regarding current trading prices, LICI.NS is priced at ₹746.00, while ICICIPRULI.NS trades at ₹513.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas ICICIPRULI.NS's P/E ratio is 54.44. In terms of profitability, LICI.NS's ROE is +0.18%, compared to ICICIPRULI.NS's ROE of +0.11%. Regarding short-term risk, LICI.NS is less volatile compared to ICICIPRULI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check ICICIPRULI.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, MFSL.BO has a market cap of 509.9B. Regarding current trading prices, LICI.NS is priced at ₹746.00, while MFSL.BO trades at ₹1,477.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas MFSL.BO's P/E ratio is 353.48. In terms of profitability, LICI.NS's ROE is +0.18%, compared to MFSL.BO's ROE of +0.02%. Regarding short-term risk, LICI.NS is less volatile compared to MFSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check MFSL.BO's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, MFSL.NS has a market cap of 509.9B. Regarding current trading prices, LICI.NS is priced at ₹746.00, while MFSL.NS trades at ₹1,477.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas MFSL.NS's P/E ratio is 354.29. In terms of profitability, LICI.NS's ROE is +0.18%, compared to MFSL.NS's ROE of +0.02%. Regarding short-term risk, LICI.NS is less volatile compared to MFSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check MFSL.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, NIVABUPA.NS has a market cap of 133.7B. Regarding current trading prices, LICI.NS is priced at ₹746.00, while NIVABUPA.NS trades at ₹72.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas NIVABUPA.NS's P/E ratio is 144.72. In terms of profitability, LICI.NS's ROE is +0.18%, compared to NIVABUPA.NS's ROE of -0.00%. Regarding short-term risk, LICI.NS is less volatile compared to NIVABUPA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check NIVABUPA.NS's competition here

LICI.NS plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LICI.NS stands at 4.7T. In comparison, RELIGARE.BO has a market cap of 73B. Regarding current trading prices, LICI.NS is priced at ₹746.00, while RELIGARE.BO trades at ₹219.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LICI.NS currently has a P/E ratio of 8.90, whereas RELIGARE.BO's P/E ratio is 70.92. In terms of profitability, LICI.NS's ROE is +0.18%, compared to RELIGARE.BO's ROE of +0.03%. Regarding short-term risk, LICI.NS is less volatile compared to RELIGARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LICI.NS.Check RELIGARE.BO's competition here